APL immunoreactive peptides, conjugates thereof and methods...

Details APL immunoreactive peptides, conjugates thereof and methods... APL immunoreactive peptides, conjugates thereof and methods...

1998-09-24

2002-06-25

Ceperley, Mary E. (Department: 1641)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acid esters

C560S142000, C560S145000

Reexamination Certificate

active

06410775

ABSTRACT:

TECHNICAL FIELD
This invention is in the field of immunology and relates to compositions and methods for treating and diagnosing antiphospholipid (aPL) antibody-mediated pathologies. More specifically, the invention relates to conjugates of chemically-defined nonimmunogenic valency platform molecules and immunospecific analogs of aPL-binding epitopes as well as methods and compositions for producing these conjugates. Optimized analogs lack T cell epitopes. In addition, the invention relates to diagnostic assays for detecting the presence of and quantitating the amount of antiphospholipid antibodies in a biological sample. The invention also relates to a method of utilizing random peptide libraries to identify immunospecific analogs of aPL-binding epitopes.
BACKGROUND OF THE INVENTION
Antiphospholipid antibodies occur in autoimmune diseases such as systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APS) as well as in association with infections and drug therapy. APS is characterized by one or more clinical features such as arterial or venous thrombosis, thrombocytopenia and fetal loss. APS may be primary or it may be associated with other conditions, primarily SLE. (Phospholipid-Binding Antibodies (Harris et al., eds., CRC Press, Boca Raton, Fla., 1991); McNeil et al. Advances in Immunology, Vol. 49, pp. 193-281 (Austen et al., eds., Academic Press, San Diego, Calif., 1991)). Approximately 30-40% of patients with SLE have aPL, however, 50% of patients with aPL antibodies do not have SLE. This 50% may have other autoimmune rheumatic diseases, miscellaneous conditions or they may have been subjected to drug therapy, particularly chlorpromazine. In one study of 70 patients, 26 males and 44 females, with primary APS (PAPS) but no evidence of SLE, the following features were observed: deep venous thrombosis (DVT) in 31; arterial occlusion in 31, particularly stroke or transient ischemia; myocardial infarctions in 15; recurrent fetal loss in 24; thrombocytopenia (TCP) in 32; 10 had a positive Coombs' test; Evans' syndrome in 7; anti-nuclear antibody (ANA) in 32, but less than 1:160 in 29; and antimitochondrial antibody (AMA) in approximately 24. (McNeil et al., supra.). Estimates vary but in about 5% of all stroke patients, aPL antibodies are thought to be an important contributing factor.
Transient aPL antibodies, such as those detected in a VDRL test, occur during many infections. Approximately 30% of patients possessing persistent aPL antibodies have suffered a thrombic event. The presence of aPL antibodies defines a group of patients within SLE who display a syndrome of clinical features consisting of one or more of thrombosis, TCP, and fetal loss. The risk of this syndrome in SLE overall is around 25%; this risk increases to 40% in the presence of aPL antibodies and decreases to 15% in their absence. Because aPL antibodies were thought to be directed at phospholipids in plasma membranes, it has been postulated that they may exert direct pathogenic effects in vivo by interfering with hemostatic processes that take place on the phospholipid membranes of cells such as platelets or endothelium. In patients with PAPS, the fact that aPL antibodies appear to be the only risk factor present is further evidence that these antibodies have a direct pathogenic role. Induction of PAPS by immunizing mice with human anticardiolipin antibodies is the best evidence yet that aPL antibodies are directly pathogenic (Bakimer et al. 1992
J. Clin. Invest.
89:1558-1563; Blank et al. 1991
Proc. Natl. Acad. Sci.
88:3069-3073).
Measurement of aPL antibodies in the clinical environment is still an imperfect art. A commercially available set of standard antisera (APL Diagnostics, Inc., Louisville, Ky.) allow generation of a standard curve for comparison of assays performed in various laboratories. A great deal of inconsistency exists, however, between the results obtained at these laboratories regarding the exact GPL and MPL, the unit of measurement for IgG and IgM antiphospholipid antibodies, respectively, ratings for given sera and the levels of GPL and MPL that are categorized as high, medium or low titer. The available commercial kits vary greatly in the values assigned to the commercially available standards (Reber et al. (1995)
Thrombosis and Haemostat.
73:444-452). In spite of these limitations, there is general agreement that the epitopes recognized by antibodies in APS, PAPS and other aPL antibody-mediated diseases including recurrent stroke and recurrent fetal loss are located in the 5th domain of &bgr;
2
-GPI and are exposed to the antibody following binding of &bgr;
2
-GPI to cardiolipin.
It is now generally accepted that aPL antibodies recognize an antigenic complex comprised of &bgr;
2
-glycoprotein I (&bgr;
2
-GPI) and negatively-charged phospholipid, e.g., cardiolipin (McNeil et al. (1990)
Proc. Natl. Acad. Sci.
87:4120-4124; Galli et al. (1990)
Lancet
1:1544-1547) (hereinafter “aPL immunogen”). &bgr;
2
-GPI is a minor plasma glycoprotein found free and in association with lipoprotein lipids where it is also known as apolipoprotein H (apo H). It consists of five independently folding domains referred to as Sushi or short consensus repeat domains that resemble similar domains in other proteins. &bgr;
2
-GPI has been reported to undergo antigenic and conformational changes upon binding phospholipid (Wagenkneckt et al. (1993)
Thromb. Haemostas.
69:361-365; Jones et al. (1992)
Proc.
5
th Intl. Symp. Antiphospholipid Antibodies
(Abstract S5)). The fifth domain contains the putative sites of lipid binding and aPL antibody binding (Hunt J. and S. Krilis, (1994)
J. Immunol
152:653-659; Lauer et al. (1993)
Immunol.
80:22-28). The pathological mechanism for aPL is unknown (McNeil et al., supra). Most explanations invoke endothelial cell function or platelet involvement (Haselaar et al. (1990)
Thromb. Haemostas.
63:169-173). These explanations suggest that following blood vessel endothelial cell injury or platelet activation, the exposure or transbilayer migration of anionic phospholipid to the plasma-exposed surface may lead to &bgr;
2
-GPI-binding and trigger aPL antibody formation.
aPL antibodies may be directly prothrombotic by reducing prostacyclin formation (Vermylen, J. and J. Arnout (1992)
J. Clin. Lab. Med.
120:10-12); by direct interference with the action of coagulation proteins; or by blocking the ability of &bgr;
2
-GPI to inhibit the intrinsic blood coagulation pathway, platelet prothrombinase activity, and ADP-mediated platelet aggregation (Arvieux et al. (1993)
Thromb. Haemostas.
60:336-341).
A major new tool in medicinal chemistry in the search for lead compounds has been the advent of combinatorial libraries providing vast molecular diversity. Molecular diversity may arise from chemical synthesis or from biological systems (Scott., J. K. Rational Drug Design (CRC Press, Weiner, D. B. and W. V. Williams, eds., Boca, Raton, Fla., 1994); Moos et al. (1993)
Ann. Reports Med. Chem.
28:315-324). By displaying random peptides on the surface of filamentous phage, epitope libraries containing hundreds of millions of clones for probing by clinically significant antibodies have been created (Scott, J. K. and G. P. Smith (1990)
Science
249:286-390; Cesareni, G. (1992)
FEBS Lett.
307:66-70). Such phage libraries are prepared by incorporating randomized oligonucleotide sequences into the phage genome, usually the pIII gene, which encode unique peptide sequences on the surface of each phage. Following sequential rounds of affinity purification and amplification, those phage that bind antibody are propagated in
E. coli
and the binding peptides identified by sequencing the corresponding coding region of viral DNA. In most cases, subsequent study will involve corresponding synthetic peptides after establishing their ability to bind antibody. Phage-based libraries have been used to mimic discontinuous epitopes (Luzzago et al. (1993)
Gene
128:51-57; BaLass et al. (1993)
Proc. Natl. Acad. Sci.
90:10638-10642). The potential plasma ins

Affiliated with

Also associated with

Rating

APL immunoreactive peptides, conjugates thereof and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with APL immunoreactive peptides, conjugates thereof and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and APL immunoreactive peptides, conjugates thereof and methods... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2907542